CA3241714A1 - Complement factor-i formulations - Google Patents

Complement factor-i formulations

Info

Publication number
CA3241714A1
CA3241714A1 CA3241714A CA3241714A CA3241714A1 CA 3241714 A1 CA3241714 A1 CA 3241714A1 CA 3241714 A CA3241714 A CA 3241714A CA 3241714 A CA3241714 A CA 3241714A CA 3241714 A1 CA3241714 A1 CA 3241714A1
Authority
CA
Canada
Prior art keywords
formulations
cfi
complement factor
variants
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3241714A
Other languages
English (en)
French (fr)
Inventor
Bing Shan
Brian David Connolly
Sibu BALAN
Anju Chatterji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CA3241714A1 publication Critical patent/CA3241714A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21045—Complement factor I (3.4.21.45)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3241714A 2021-12-22 2022-12-21 Complement factor-i formulations Pending CA3241714A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163293013P 2021-12-22 2021-12-22
US63/293,013 2021-12-22
PCT/US2022/082179 WO2023122691A1 (en) 2021-12-22 2022-12-21 Complement factor-i formulations

Publications (1)

Publication Number Publication Date
CA3241714A1 true CA3241714A1 (en) 2023-06-29

Family

ID=85172701

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3241714A Pending CA3241714A1 (en) 2021-12-22 2022-12-21 Complement factor-i formulations

Country Status (10)

Country Link
US (1) US20250009855A1 (enExample)
EP (1) EP4452321A1 (enExample)
JP (1) JP2025503483A (enExample)
KR (1) KR20240124950A (enExample)
CN (1) CN118450906A (enExample)
AU (1) AU2022420007A1 (enExample)
CA (1) CA3241714A1 (enExample)
IL (1) IL313777A (enExample)
MX (1) MX2024007731A (enExample)
WO (1) WO2023122691A1 (enExample)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201821082D0 (en) * 2018-12-21 2019-02-06 Gyroscope Therapeutics Ltd Combination of complement factors i and h, and vector encoding thereof
WO2021081348A1 (en) * 2019-10-23 2021-04-29 Gemini Therapeutics Inc. Methods for treating patients having cfi mutations with recombinant cfi proteins
CA3182800A1 (en) * 2020-06-14 2021-12-23 Vertex Pharmaceuticals Inc. Complement factor i-related compositions and methods

Also Published As

Publication number Publication date
AU2022420007A1 (en) 2024-06-20
WO2023122691A1 (en) 2023-06-29
EP4452321A1 (en) 2024-10-30
IL313777A (en) 2024-08-01
JP2025503483A (ja) 2025-02-04
US20250009855A1 (en) 2025-01-09
CN118450906A (zh) 2024-08-06
KR20240124950A (ko) 2024-08-19
MX2024007731A (es) 2024-07-01

Similar Documents

Publication Publication Date Title
WO2000044443A3 (en) Intra-pericardial delivery of anti-microtubule agents
CA2360248A1 (en) Combinations of formoterol and a tiotropium salt
WO2001036603A3 (en) Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
WO2001012122A3 (en) Method and system for treating cardiac arrest using hypothermia
EP1073443A4 (en) METHOD OF PREPARING A BLOOD PRODUCT STABILIZED BY DIAFILTRATION
CA2123049A1 (en) Pharmaceutical containing the p40 subunit of interleukin 12
WO2000071108A3 (en) Methods for treatment of asthma using s-oxybutynin
EP0652957A1 (en) COMPOSED VIRUS PARTICLES AND THEIR USE IN A VACCINE AGAINST A ROTAVIRUS DISEASE.
CA3241714A1 (en) Complement factor-i formulations
WO1995016435A3 (en) Improved intraocular irrigating solution containing non-steroidal antiinflammatory agent
Uysal et al. High-dose oral methylprednisolone therapy in childhood hemangiomas
CA2373252A1 (en) Long lasting anti-angiogenic peptides
WO2004010934A3 (en) Methods for the use of neurotoxin in the treatment of urologic disorders
WO2002029099A1 (fr) Technique de criblage de substance physiologiquement active
IE890719L (en) Modified proteins
Poole-Wilson The NETWORK study. The effect of dose of an ACE-inhibitor on outcome in patients with heart failure
Blondeau et al. Cardiovascular effects of epinephrine and dipivefrin in patients using timolol: a single-dose study
Wolff-Kormann et al. Successful treatment with hydroxyurea of ocular involvement in chronic myelomonocytic leukemia
WO2003077796A3 (en) Ophthalmic solutions for delivery of expression vectors
WO2002014474A3 (en) Method of treating alzheimer's disease with cell therapy
莊朝傑 et al. Silicone Oil Keratopathy
Roehr Another failed promise? NTZ gets the nix
WO2024077259A3 (en) Compositions and methods for degradation of lipofuscin cycloretinal by msp1
Lee et al. The effect of subtenon injection of methylprednisolone acetate on the breakdown of blood retinal barrier after cryotherapy
WO1995006717A3 (en) Methods of suppressing graft rejection

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W160 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: COVER PAGE PUBLISHED

Effective date: 20240703

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20241114

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241213

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241213